<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02044393</url>
  </required_header>
  <id_info>
    <org_study_id>1334.10</org_study_id>
    <secondary_id>2013-003814-42</secondary_id>
    <nct_id>NCT02044393</nct_id>
  </id_info>
  <brief_title>Interaction of BI 691751 With Itraconazole</brief_title>
  <official_title>Relative Bioavailability of a Single Oral Dose of BI 691751 When Administered Alone or in Combination With Multiple Oral Doses of Itraconazole in Healthy Male Subjects (an Open-label, Randomised, Two-period, Two-sequence Crossover Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Investigation of the relative bioavailability of a single dose of BI 691751 when given alone
      and together with itraconazole; safety and tolerability
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-tz (Area Under the Concentration-time Curve of BI 691751 in Plasma and Whole Blood Over the Time Interval From 0 up to the Last Quantifiable Concentration)</measure>
    <time_frame>from day 1 to 31 days postdose relative to BI 691751 administration (h:min): -2:00, 0:10, 0:20, 0:40, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00, 119:00, 143:00, 215:00, 287:00, 383:00, 551:00, 719:00h.</time_frame>
    <description>AUC0-tz: area under the concentration-time curve of BI 691751 in plasma and whole blood over the time interval from 0 up to the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum Measured Concentration of BI 691751 in Plasma and Whole Blood)</measure>
    <time_frame>From day 1 to 31 days postdose relative to BI 691751 administration (h:min): -2:00, 0:10, 0:20, 0:40, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00, 119:00, 143:00, 215:00, 287:00, 383:00, 551:00, 719:00h.</time_frame>
    <description>Cmax (maximum measured concentration of BI 691751 in plasma and whole blood).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-infinity (Area Under the Concentration-time Curve of BI 691751 in Plasma and Whole Blood Over the Time Interval From 0 Extrapolated to Infinity)</measure>
    <time_frame>from day 1 to 31 days postdose relative to BI 691751 administration time: -2:00, 0:10, 0:20, 0:40, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00, 119:00, 143:00, 215:00, 287:00, 383:00, 551:00, 719:00h.</time_frame>
    <description>AUC0-infinity (area under the concentration-time curve of BI 691751 in plasma and whole blood over the time interval from 0 extrapolated to infinity).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose BI 691751</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multiple doses of itraconazole + single dose BI 691751</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>multiple doses of itraconazole given as capsules</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>single dose BI 691751 given as tablet</description>
    <arm_group_label>Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 691751</intervention_name>
    <description>single dose BI 691751 given as tablet</description>
    <arm_group_label>Reference</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy male subjects

          2. body mass index (BMI) of 18.5 to 29.9 kg/m2

          3. Subjects must be able to understand and comply with study requirements

        Exclusion criteria:

          1. Any finding in the medical examination (including blood pressure (BP), pulse rate
             (PR), or electrocardiogram (ECG)) deviating from normal and judged clinically relevant
             by the investigator.

          2. Pulse rate outside 45 to 100 bpm or repeated measurements of systolic BP outside 90 to
             140 mmHg or diastolic BP outside 50 to 90 mmHg.

          3. Any laboratory value outside the reference range that the investigator considers to be
             of clinical relevance

          4. Any alanine transaminase (ALT/GPT), aspartate transaminase (AST/GOT), or
             gammaglutamyltransferase (GGT) value outside the reference range at the screening
             examination

          5. Any evidence of a concomitant disease judged clinically relevant by the investigator

          6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological, or hormonal disorders

          7. Any history of relevant liver diseases such as disturbance of liver function,
             jaundice, drug induced liver injury, Dubin-Johnson syndrome, Rotor syndrome, or liver
             tumors
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1334.10.1 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Biberach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com/</url>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2014</study_first_submitted>
  <study_first_submitted_qc>January 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 24, 2014</study_first_posted>
  <results_first_submitted>November 11, 2015</results_first_submitted>
  <results_first_submitted_qc>November 11, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 16, 2015</results_first_posted>
  <last_update_submitted>November 11, 2015</last_update_submitted>
  <last_update_submitted_qc>November 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Hydroxyitraconazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Itraconazole (IT) +BI 691751 / BI 691751</title>
          <description>Subjects in treatment sequence of tested drug treatment in period 1, then reference drug treatment in period 2 (T/R): two capsules of 100 mg itraconazole were given twice daily on Day -3 (loading dose) and once daily on Day -2 to Day 7 (10 days of itraconazol treatment in total). In addition, 1 tablet of 10 mg BI 691751 was given as a single dose on Day 1 (corresponding to the fourth day of the 10-day itraconazole treatment) in period 1. One tablet of 10 mg BI 691751 was given as a single dose on Day 1 in period 2.
The BI 691751 single dose administrations in the 2 treatment periods were separated by a washout period of at least 7 weeks.
Oral administration with 240 mL water after intake of a standardised meal.</description>
        </group>
        <group group_id="P2">
          <title>BI 691751 / IT+BI 691751</title>
          <description>Subjects in treatment sequence of reference drug treatment in period 1, then tested drug treatment in period 2 (R/T): One tablet of 10 mg BI 691751 was given as a single dose on Day 1 in period 1. Two capsules of 100 mg itraconazole were given twice daily on Day -3 (loading dose) and once daily on Day -2 to Day 7 (10 days of itraconazol treatment in total), and, 1 tablet of 10 mg BI 691751 was given as a single dose on Day 1 (corresponding to the fourth day of the 10-day itraconazole treatment) in period 2.
Oral administration with 240 mL water after intake of a standaridsed meal.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set (TS): included all subjects who were randomized and took at least one dose of study medication during the trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Itraconazole (IT) +BI 691751 / BI 691751</title>
          <description>Subjects in treatment sequence of tested drug treatment in period 1, then reference drug treatment in period 2 (T/R): two capsules of 100 mg itraconazole were given twice daily on Day -3 (loading dose) and once daily on Day -2 to Day 7 (10 days of itraconazol treatment in total). In addition, 1 tablet of 10 mg BI 691751 was given as a single dose on Day 1 (corresponding to the fourth day of the 10-day itraconazole treatment) in period 1. One tablet of 10 mg BI 691751 was given as a single dose on Day 1 in period 2.
The BI 691751 single dose administrations in the 2 treatment periods were separated by a washout period of at least 7 weeks.
Oral administration with 240 mL water after intake of a standardised meal.</description>
        </group>
        <group group_id="B2">
          <title>BI 691751 / IT+BI 691751</title>
          <description>Subjects in treatment sequence of reference drug treatment in period 1, then tested drug treatment in period 2 (R/T): One tablet of 10 mg BI 691751 was given as a single dose on Day 1 in period 1. Two capsules of 100 mg itraconazole were given twice daily on Day -3 (loading dose) and once daily on Day -2 to Day 7 (10 days of itraconazol treatment in total), and, 1 tablet of 10 mg BI 691751 was given as a single dose on Day 1 (corresponding to the fourth day of the 10-day itraconazole treatment) in period 2.
Oral administration with 240 mL water after intake of a standaridsed meal.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.1" spread="9.9"/>
                    <measurement group_id="B2" value="37.4" spread="6.6"/>
                    <measurement group_id="B3" value="36.3" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0-tz (Area Under the Concentration-time Curve of BI 691751 in Plasma and Whole Blood Over the Time Interval From 0 up to the Last Quantifiable Concentration)</title>
        <description>AUC0-tz: area under the concentration-time curve of BI 691751 in plasma and whole blood over the time interval from 0 up to the last quantifiable concentration.</description>
        <time_frame>from day 1 to 31 days postdose relative to BI 691751 administration (h:min): -2:00, 0:10, 0:20, 0:40, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00, 119:00, 143:00, 215:00, 287:00, 383:00, 551:00, 719:00h.</time_frame>
        <population>Pharmacokinetic Set (PKS): included all subjects from the TS who provided at least one primary or secondary pharmacokinetic endpoint in any period that is judged as evaluable for pharmacokinetics and is not affected by protocol violations relevant to the statistical evaluation of bioavailability</population>
        <group_list>
          <group group_id="O1">
            <title>BI 691751</title>
            <description>single dose BI 691751
BI 691751: 10 mg single dose oral administration with 240 mL water after intake of a standard meal.</description>
          </group>
          <group group_id="O2">
            <title>IT + BI 691751</title>
            <description>Two capsules of 100 mg IT were given twice daily on Day -3 and once daily on Day -2 to Day 7. 1 tablet of 10 mg BI 691751 was given as a single dose on Day 1 with 240 mL water after intake of a standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-tz (Area Under the Concentration-time Curve of BI 691751 in Plasma and Whole Blood Over the Time Interval From 0 up to the Last Quantifiable Concentration)</title>
          <description>AUC0-tz: area under the concentration-time curve of BI 691751 in plasma and whole blood over the time interval from 0 up to the last quantifiable concentration.</description>
          <population>Pharmacokinetic Set (PKS): included all subjects from the TS who provided at least one primary or secondary pharmacokinetic endpoint in any period that is judged as evaluable for pharmacokinetics and is not affected by protocol violations relevant to the statistical evaluation of bioavailability</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>in plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2830" spread="34.6"/>
                    <measurement group_id="O2" value="2090" spread="43.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>in whole blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25000" spread="25.8"/>
                    <measurement group_id="O2" value="21600" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>gMean ratio of IT+BI 691751 to BI 69175 treatment (in plasma)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% confidence interval for gMean ratio of IT+BI 691751 to BI 69175 treatment was provided.
The ANOVA model included the fixed effects 'sequence', 'period' and 'treatment' and as a random effect 'subject within sequence' as source of variation.</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>74.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>32.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.371</ci_lower_limit>
            <ci_upper_limit>87.959</ci_upper_limit>
            <estimate_desc>ratio of IT+BI 691751 to BI 691751 treatment. Estimated value and its confidence interval (CI) are in percentage unit.
The standard error of the mean actually is the geometric coefficient of variance.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>gMean ratio of IT+BI 691751 to BI 691751 treatment (in whole blood)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% confidence interval for gMean ratio of IT+BI 691751 to BI 69175 treatment was provided.
The ANOVA model included the fixed effects 'sequence', 'period' and 'treatment' and as a random effect 'subject within sequence' as source of variation.</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>86.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>18.6</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.04</ci_lower_limit>
            <ci_upper_limit>95.56</ci_upper_limit>
            <estimate_desc>ratio of IT+BI 691751 to BI 691751 treatment. Estimated value and its confidence interval (CI) are in percentage unit.
The standard error of the mean actually is the geometric coefficient of variance.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cmax (Maximum Measured Concentration of BI 691751 in Plasma and Whole Blood)</title>
        <description>Cmax (maximum measured concentration of BI 691751 in plasma and whole blood).</description>
        <time_frame>From day 1 to 31 days postdose relative to BI 691751 administration (h:min): -2:00, 0:10, 0:20, 0:40, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00, 119:00, 143:00, 215:00, 287:00, 383:00, 551:00, 719:00h.</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 691751</title>
            <description>10 mg BI 691751 single dose oral administration with 240 mL water after intake of a standard meal.</description>
          </group>
          <group group_id="O2">
            <title>IT + BI 691751</title>
            <description>Two capsules of 100 mg IT were given twice daily on Day -3 and once daily on Day -2 to Day 7. 1 tablet of 10 mg BI 691751 was given as a single dose on Day 1 with 240 mL water after intake of a standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax (Maximum Measured Concentration of BI 691751 in Plasma and Whole Blood)</title>
          <description>Cmax (maximum measured concentration of BI 691751 in plasma and whole blood).</description>
          <population>PKS</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>in plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="157" spread="24.4"/>
                    <measurement group_id="O2" value="150" spread="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>in whole blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217" spread="16.0"/>
                    <measurement group_id="O2" value="203" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>gMean ratio of test to reference treatment (in plasma)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% confidence interval for gMean ratio of IT+BI 691751 to BI 69175 treatment was provided.
The ANOVA model included the fixed effects 'sequence', 'period' and 'treatment' and as a random effect 'subject within sequence' as source of variation.</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>95.59</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>23.5</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>84.195</ci_lower_limit>
            <ci_upper_limit>108.537</ci_upper_limit>
            <estimate_desc>ratio of test to reference treatment. The standard error of the mean actually is the geometric coefficient of variance.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>gMean ratio of test to reference treatment (in whole blood)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% confidence interval for gMean ratio of IT+BI 691751 to BI 69175 treatment was provided.
The ANOVA model included the fixed effects 'sequence', 'period' and 'treatment' and as a random effect 'subject within sequence' as source of variation.</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>93.54</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>15.1</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.142</ci_lower_limit>
            <ci_upper_limit>101.570</ci_upper_limit>
            <estimate_desc>ratio of test to reference treatment. The standard error of the mean actually is the geometric coefficient of variance.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-infinity (Area Under the Concentration-time Curve of BI 691751 in Plasma and Whole Blood Over the Time Interval From 0 Extrapolated to Infinity)</title>
        <description>AUC0-infinity (area under the concentration-time curve of BI 691751 in plasma and whole blood over the time interval from 0 extrapolated to infinity).</description>
        <time_frame>from day 1 to 31 days postdose relative to BI 691751 administration time: -2:00, 0:10, 0:20, 0:40, 1:00, 1:30, 2:00, 3:00, 4:00, 6:00, 8:00, 10:00, 12:00, 24:00, 34:00, 47:00, 71:00, 95:00, 119:00, 143:00, 215:00, 287:00, 383:00, 551:00, 719:00h.</time_frame>
        <population>PKS</population>
        <group_list>
          <group group_id="O1">
            <title>BI 691751</title>
            <description>10 mg BI 691751 single dose oral administration with 240 mL water after intake of a standard meal.</description>
          </group>
          <group group_id="O2">
            <title>IT + BI 691751</title>
            <description>Two capsules of 100 mg IT were given twice daily on Day -3 and once daily on Day -2 to Day 7. 1 tablet of 10 mg BI 691751 was given as a single dose on Day 1 with 240 mL water after intake of a standard meal.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-infinity (Area Under the Concentration-time Curve of BI 691751 in Plasma and Whole Blood Over the Time Interval From 0 Extrapolated to Infinity)</title>
          <description>AUC0-infinity (area under the concentration-time curve of BI 691751 in plasma and whole blood over the time interval from 0 extrapolated to infinity).</description>
          <population>PKS</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>in plasma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3160" spread="34.8"/>
                    <measurement group_id="O2" value="2360" spread="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>in whole blood</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27700" spread="29.6"/>
                    <measurement group_id="O2" value="24600" spread="29.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>gMean ratio of IT+BI 691751 to BI 691751 treatment (in plasma)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% confidence interval for gMean ratio of IT+BI 691751 to BI 69175 treatment was provided.
The ANOVA model included the fixed effects 'sequence', 'period' and 'treatment' and as a random effect 'subject within sequence' as source of variation.</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>74.86</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>32.4</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.946</ci_lower_limit>
            <ci_upper_limit>89.035</ci_upper_limit>
            <estimate_desc>ratio of IT+BI 691751 to BI 691751 treatment. The standard error of the mean actually is the geometric coefficient of variance.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>gMean ratio of IT+BI 691751 to BI 691751 treatment (in whole blood)</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>90% confidence interval for gMean ratio of IT+BI 691751 to BI 69175 treatment was provided.
The ANOVA model included the fixed effects 'sequence', 'period' and 'treatment' and as a random effect 'subject within sequence' as source of variation.</non_inferiority_desc>
            <param_type>gMean ratio</param_type>
            <param_value>88.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>20.7</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>78.60</ci_lower_limit>
            <ci_upper_limit>98.95</ci_upper_limit>
            <estimate_desc>ratio of IT+BI 691751 to BI 691751 treatment. The standard error of the mean actually is the geometric coefficient of variance.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From the 1st trial drug administration of a treatment until the 1st trial drug intake in the next treatment or until 31 days after the last administration of BI were assigned to the respective on-treatment phases (BI alone, loading IT, BI + further IT)</time_frame>
      <desc>More specifically, for: BI 691751 - up to 50 days, Loading IT - 3 days, BI + further IT - up to 47 days</desc>
      <group_list>
        <group group_id="E1">
          <title>BI 691751</title>
          <description>10 mg single dose oral administration with 240 mL water after intake of a standard meal. (only in the reference treatment period)</description>
        </group>
        <group group_id="E2">
          <title>Loading Itraconazole (IT)</title>
          <description>200 mg of itraconazole (introductory treatment with itraconazole over three days, prior to the first administration of BI 691751 only in the test treatment period).</description>
        </group>
        <group group_id="E3">
          <title>BI 691751 + Further IT</title>
          <description>10 mg of BI 691751 in combination with multiple oral doses of itraconazole (only in the test treatment period after the introductory treatment with itraconazole alone over three days).</description>
        </group>
        <group group_id="E4">
          <title>Total BI 691751</title>
          <description>total subjects with BI 691751 treatment (either BI 691751 alone or IT+BI 691751)</description>
        </group>
        <group group_id="E5">
          <title>Total on Treatment</title>
          <description>combination of BI 691751, loading IT and BI 691751+ further IT.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

